A pivotal discovery of this study lies in the synergistic application of Lipo and CXB, which markedly improves immunotherapy efficacy against obese CRC by regulating lipid metabolism and inflammatory responses via suppression of the arachidonic acid (AA)/COX-2/PGE2 axis. Here, PTGS2 is linked to colorectal carcinoma.